Johnson & Johnson reported $25.4B in revenue (+5.9% YoY), compared with a +7.2% median across covered Health Care peers. Insider tracks 1 open management expectation for this company. 1 insider sale recorded.
Johnson & Johnson announced plans to acquire drug developer Ollin Biosciences and received regulatory clearance for expanded use of a surgical instrument. These strategic moves aim to strengthen its ophthalmology and medical technology portfolio.
Johnson & Johnson reported $25.4 billion in worldwide revenue for the third quarter, released on October 21, 2026. Net income was $210 million. Diluted earnings per share (EPS) fell to $0.09 from $2.12 a year earlier.
Johnson & Johnson said ERLEADA given before and after surgery reduced the risk of recurrence or death by 62% compared with surgery alone in patients with high-risk prostate cancer. For shareholders, this is an update on clinical data, but the source does not report a financial impact.
On October 13, 2026, Johnson & Johnson announced market authorization of the OTTAVA system – the world’s first robotic device integrated into an operating table – approval of IMAAVY for warm autoimmune hemolytic anemia (wAIHA) and the start of priority review for RYBREVANT FASPRO for advanced head and neck cancer. The moves expand the company’s portfolio in robotic surgery, hematology and oncology.
JOHNSON & JOHNSON: 12 recorded developments from 1 official source in 2026-10.
2026-10-21: Revenue (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), quarter 2026-06-29 to 2026-09-27: 25,399,000,000 USD (25.4 billion; 25,399 million); same period a year earlier (2025-06-30 to 2025-09-28): 23,993,000,000 USD (24 billion; 23,993 million); change +5.9%Source
2026-10-21: Revenue (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), year to date 2025-12-29 to 2026-09-27: 74,771,000,000 USD (74.8 billion; 74,771 million); same period a year earlier (2024-12-30 to 2025-09-28): 69,629,000,000 USD (69.6 billion; 69,629 million); change +7.4%Source
2026-10-21: Gross profit (us-gaap:GrossProfit), quarter 2026-06-29 to 2026-09-27: 17,302,000,000 USD (17.3 billion; 17,302 million); same period a year earlier (2025-06-30 to 2025-09-28): 16,690,000,000 USD (16.7 billion; 16,690 million); change +3.7%Source
2026-10-21: Gross profit (us-gaap:GrossProfit), year to date 2025-12-29 to 2026-09-27: 50,517,000,000 USD (50.5 billion; 50,517 million); same period a year earlier (2024-12-30 to 2025-09-28): 47,341,000,000 USD (47.3 billion; 47,341 million); change +6.7%Source
2026-10-21: Net income (us-gaap:NetIncomeLoss), quarter 2026-06-29 to 2026-09-27: 210,000,000 USD (210 million); same period a year earlier (2025-06-30 to 2025-09-28): 5,152,000,000 USD (5.2 billion; 5,152 million); change -95.9%Source
2026-10-21: Net income (us-gaap:NetIncomeLoss), year to date 2025-12-29 to 2026-09-27: 10,979,000,000 USD (11 billion; 10,979 million); same period a year earlier (2024-12-30 to 2025-09-28): 21,688,000,000 USD (21.7 billion; 21,688 million); change -49.4%Source
2026-10-21: Operating cash flow (us-gaap:NetCashProvidedByUsedInOperatingActivities), year to date 2025-12-29 to 2026-09-27: 18,850,000,000 USD (18.9 billion; 18,850 million); same period a year earlier (2024-12-30 to 2025-09-28): 17,221,000,000 USD (17.2 billion; 17,221 million); change +9.5%Source
2026-10-21: Capital expenditure (us-gaap:PaymentsToAcquirePropertyPlantAndEquipment), year to date 2025-12-29 to 2026-09-27: 3,732,000,000 USD (3.7 billion; 3,732 million); same period a year earlier (2024-12-30 to 2025-09-28): 2,995,000,000 USD (3 billion; 2,995 million); change +24.6%Source
2026-10-21: Cash and cash equivalents (us-gaap:CashAndCashEquivalentsAtCarryingValue), as of 2026-09-27: 16,910,000,000 USD (16.9 billion; 16,910 million); previous balance (2025-12-28): 19,709,000,000 USD (19.7 billion; 19,709 million); change -14.2%Source
2026-10-21: Total liabilities (us-gaap:Liabilities), as of 2026-09-27: 115,896,000,000 USD (115.9 billion; 115,896 million); previous balance (2025-12-28): 117,666,000,000 USD (117.7 billion; 117,666 million); change -1.5%Source
Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.
Key figures
From the 10-Q for the period ended September 27, 2026, filed October 21, 2026. SEC
Latest
Earlier
Change
Revenue quarter
$25.4B
$24B
+5.9%
Net income quarter
$210M
$5.2B
-95.9%
Diluted EPS quarter
$0.09
$2.12
-95.8%
Operating cash flow year to date
$18.9B
$17.2B
+9.5%
Cash and cash equivalents balance
$16.9B
$19.7B
-14.2%
Long-term debt balance
$35.8B
$39.4B
-9.2%
Next results expected around January 20, 2027 (estimate: the quarter ending about December 27, 2026 plus the 24 days the last report took). The company announces the actual date.
As the company tagged them in its filing (SEC XBRL). Quarter and year figures are compared with the same period a year earlier, balances with the previous balance sheet. Download CSV
Sector peers
How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.
Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.
Expectations and reality
Open
This program is expected to be substantially completed by the end of fiscal year 2026.
Said October 13, 2026 · Period named: end of fiscal year 2026 · Source · Our article
Not yet checked against later reports.
What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.
Governance events
Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.
Date
Event
Filing
August 4, 2026
Director or officer departure or appointment (8-K item 5.02)
As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.
From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.